Clinical Laboratory Results as Prognosis Marker in Advanced Stage Non-small Cell Lung Cancer (NSCLC) in Indonesia

Background: Lung cancer is the most common cause of cancer-related death among men in the world. Given the very high mortality caused by lung cancer, a biological marker to determine a more sensitive therapy among non-small cell lung cancer (NSCLC) patients is needed. This study aims to demonstrate...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2022-09, Vol.14 (9), p.e29386-e29386
Main Authors: Hanafi, Arif R, Jayusman, Achmad M, Sutandyo, Noorwati, Kurniawati, Sri, Setiawan, Lyana, Diandra, Alyssa, Hidayat, Kusmantoro
Format: Article
Language:English
Subjects:
Anemia
Antigens
Biomarkers
Cancer therapies
Creatinine
Electrolytes
Growth factors
Hemoglobin
Hyponatremia
Internal Medicine
Kinases
Laboratories
Lung cancer
Medical diagnosis
Medical prognosis
Medical records
Mortality
Mutation
Oncology
Pathology
Patients
Potassium
Pulmonology
Quality of life
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Lung cancer is the most common cause of cancer-related death among men in the world. Given the very high mortality caused by lung cancer, a biological marker to determine a more sensitive therapy among non-small cell lung cancer (NSCLC) patients is needed. This study aims to demonstrate that the clinical laboratory result can be a prognosis marker in NSCLC patients in Indonesia.Methods: This study was a retrospective cohort study. The sample was obtained from the patient's serum and the examined routine blood test (hemoglobin, leukocyte, platelets), hemostasis (fibrinogen and D-dimers), blood chemistry test (aspartate transaminase [AST], alanine transaminase [ALT], albumin, urea, creatinine, and blood glucose), electrolyte (sodium, potassium, chloride, and calcium) and tumor markers (carcinoembryonic antigen [CEA] and Cyfra 21-1). Data were analyzed and interpreted using SPSS (IBM Corp., Armonk, NY, USA). Analysis of the data was done to find the survival rate of sociodemographic variables, clinicopathologic variables, and clinic laboratory variables.Results: The study findings showed statistically significant results that were poor prognosis for these following conditions: performance status (PS) 3-4 median survival (MS):26 days, p=
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.29386